1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
U.S. Stem Cell, Inc.

U.S. Stem Cell, Inc.

USRM
U.S. Stem Cell, Inc.US flagOther OTC
0.00
USD
- -
- -
64,151.00Market Cap
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
TTM
Revenue per Share
1.71
0.31
0.42
0.38
4.21
2.4
0.13
0.02
0.02
0.01
- -
- -
- -
- -
Basic EPS, GAAP
-189.92
-82.28
-27.42
-12.48
-4.61
-1.8
-0.09
-0.01
-0.01
-0.01
-0.01
-0.01
- -
- -
Free Cash Flow per Basic Share
-69.73
-29.67
-7.48
-7.64
-2.29
-0.93
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-3,912.48
-1,943.03
-784.2
-467.78
-246.45
-133.84
-5.14
-0.41
-0.35
-0.33
-0.32
-0.3
- -
-0.25
Tangible Book Value per Share
-442.31
-210.38
-99.65
-54.67
-22.33
-8.49
-0.33
-0.02
-0.02
-0.02
-0.03
-0.03
- -
-0.03
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
1
24
309
366
398
429
461
- -
577
Sales/Revenue/Turnover
- -
- -
- -
- -
2
2
3
6
7
3
- -
- -
- -
- -
Operating Margin (%)
-7,041.44
-14,919.54
-4,148.07
-2,947.13
-171.68
-118.92
-37.61
-14.58
-16.38
-111.22
-866.24
-1,063.94
-2,096.9
-2,096.9
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-5
-5
-4
-3
-2
-2
-2
-3
-2
-4
-3
-3
-3
-3
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-11,123.59
-26,878.61
-6,572.63
-3,271.33
-109.62
-74.93
-67.15
-63.06
-32.24
-124.84
-1,043.17
-1,637.58
-3,483.21
-3,483.21
Working Capital
-11
-12
-14
-14
-11
-6
-6
-5
-4
-9
-11
-12
-14
-14
LT Debt
1
- -
- -
- -
- -
2
2
2
3
1
1
1
1
1
Total Equity
-12
-12
-15
-14
-11
-8
-8
-7
-7
-9
-12
-13
-15
-15
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'22
Sep'22
Dec'22
ST Debt
8
8
8
LT Borrowings
1
1
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
598
632
634
Market Capitalization
3
4
3

Working Capital

FRC

•

in mil. unless spec.
Jun'22
Sep'22
Dec'22
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
13
14
14
Payables & Accruals
5
5
5
ST Debt
8
8
8
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.93%
16.51%
15.5%
Free Cash Flow
66.92%
-72.55%
-71.18%
Net Income, GAAP
3.27%
3.12%
-13.06%
Sales/Revenue/Turnover
201.27%
-42.09%
-59.13%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
-0.01
2021
- -
- -
- -
- -
-0.01
2022
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Michael Tomas
Full Time Employees
11
Sector
Healthcare
Industry
Biotechnology
Address
1560 Sawgrass Corporate Parkway Sunrise FL United States of America 33323
IPO Date
Feb 19, 2008
CIK
0001388319
Website
us-stemcell.com
Similar Companies
Solarvest BioEnergy Inc. (SVS.V)
ToolGen Inc (199800.KS)
Stoke Therapeutics, Inc. (STOK)
Medigene AG (MDGEF)
Edesa Biotech, Inc. (EDSA)
TransThera Sciences (Nanjing) Inc. (2617.HK)
Business
U.S. Stem Cell, Inc. (OTC:USRM) develops proprietary physician-based stem cell therapies and novel regenerative medicine solutions for patients with degenerative conditions, including autologous cellular therapies focused on repairing damaged tissue such as cardiac muscle; the company offers core products including the AdipoCellTM clinical protocol and kit for isolating intact patient-derived stem cells from adipose tissue, MyoCellR muscle stem cell therapy for improving cardiac function post-heart attack, and MyoCell SVF-1TM for enhanced stromal vascular fraction-based cardiac repair, alongside veterinary stem cell products for high-end equine and pet applications, physician training and certification programs serving over 700 practitioners worldwide, cell collection and storage services, and management of stem cell clinics with four locations in the United States and additional sites globally. Founded in 1999 and headquartered in Sunrise, Florida, U.S. Stem Cell operates across six continents through a network of physicians, has treated over 10,000 patients, invested more than $125 million in research and development, and developed over 30 protocols without using harmful drugs for cell isolation. In recent developments, the company continues advancing MyoCellR and MyoCell SVF-1TM toward next-phase clinical trials with FDA approvals in place for patient enrollment and an IND application, seeks commercialization partners for these cardiac therapies demonstrating preclinical improvements in heart function and blood vessel formation, restructured post-2022 to emphasize its animal health division including VetBiologics for pet regenerative medicine and wellness amid human therapy regulatory challenges, and benefited from a favorable 2022 California federal court ruling affirming that similar stromal vascular fraction procedures qualify as surgical exceptions rather than regulated drugs.